BCIP Life Sciences Associates, LP 的 Form 4 申報
Xilio Therapeutics, Inc.XLO，2021/12/10 申報
- 申報編號
- 0000899243-21-047829
- 申報時間
- 2021/12/10 20:33 ET
- 交易日
- 2021/12/8-12/10
- 申報延遲
- 2 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 4 筆非衍生性交易。公開市場買進合計 $41.0 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| BCIP Life Sciences Associates, LPCIK 0001702921 | 持股 10% 以上大股東 |
| Bain Capital Life Sciences Investors, LLCCIK 0001703031 | 持股 10% 以上大股東 |
| Bain Capital Life Sciences Fund II, L.P.CIK 0001773187 | 持股 10% 以上大股東 |
| Bain Capital Life Sciences Investors II, LLCCIK 0001796155 | 持股 10% 以上大股東 |
| BCLS II Investco, LPCIK 0001818893 | 持股 10% 以上大股東 |
| BCLS II Investco (GP), LLCCIK 0001819101 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.41 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.53 to $10.00, inclusive.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.07 to $10.00, inclusive.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $10.13 to $10.25, inclusive.
表 I 有 1 筆交易的價格引用這則附註。
備註
Exhibit 99.1: Joint Filer Information